FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171690098> ?p ?o ?g. }

• W3171690098 endingPage "167" @default.
• W3171690098 startingPage "166" @default.
• W3171690098 abstract "The authors regret that there was an error in Table 4 and apologize for any inconvenience caused. The correct Table 4 is as follows: Table 4 Incidence of Treatment-Emergent Adverse Events Related to Any Study Drug Occurring in >10 % of Patients with Advanced Lung Cancer (N = 54)Tabled 1NSQ(n = 16)SQ-A(n = 15)SQ-B(n = 6)SCLC(n = 17)Total(N = 54)Any GradeGrade ≥3Any GradeGrade ≥3Any GradeGrade≥3Any GradeGrade ≥3Any GradeGrade ≥3Patients with ≥1 AE16 (100.0)11 (68.8)15 (100.0)13 (86.7)6 (100.0)2 (33.3)17 (100.0)13 (76.5)54 (100.0)39 (72.2)Anemia13 (81.3)2 (12.5)10 (66.7)2(13.3)5(83.3)1 (16.7)15(88.2)5(29.4)43(79.6)10 (18.5)Decreased WBC count11 (68.8)4 (25.0)13 (86.7)2(13.3)3(50.0)013(76.5)1(5.9)40(74.1)7(13.0)Decreased neutrophil count11 (68.8)6 (37.5)12 (80.0)11 (73.3)3(50.0)1 (16.7)13(76.5)8(47.1)39(72.2)26 (48.1)Decreased plateletcount7(43.8)2 (12.5)5(33.3)03(50.0)1 (16.7)8(47.1)4(23.5)23(42.6)7(13.0)Increased ALT7(43.8)1(6.3)4(26.7)2(13.3)2(33.3)07(41.2)020(37.0)3(5.6)Increased AST7(43.8)06(40.0)1(6.7)2(33.3)05(29.4)020(37.0)1(1.9)Asthenia8(50.0)1(6.3)7(46.7)02(33.3)02(11.8)019(35.2)1(1.9)Decreased appetite6(37.5)04(26.7)02(33.3)07(41.2)019(35.2)0Nausea3(18.8)06(40.0)02(33.3)07(41.2)1(5.9)18(33.3)1(1.9)Vomiting2(12.5)02(13.3)01(16.7)09(52.9)1(5.9)14(25.9)1(1.9)Thrombocytopenia3(18.8)03(20.0)1(6.7)007(41.2)5 (29.4)13(24.1)6(11.1)Alopecia1(6.3)07(46.7)0005(29.4)013(24.1)0Leukopenia2(12.5)000006(35.3)08(14.8)0Neutropenia3(18.8)1(6.3)00005(29.4)3 (17.6)8(14.8)4(7.4)Rash1(6.3)03(20.0)01(16.7)02(11.8)07(13.0)0 Open table in a new tab Data presented as n (%). Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NSCLC, non-small cell lung cancer; NSQ, nonsquamous NSCLC; SCLC, small cell lung cancer; SQ-A, squamous NSCLC cohort A (tislelizumab + paclitaxel + cisplatin/carboplatin); SQ-B, squamous NSCLC cohort B (tislelizumab + gemcitabine + cisplatin/carboplatin); WBC, white blood cell. The incorrect Table 4 was previously published as follows: Table 4 Incidence of Treatment-Emergent Adverse Events Related to Any Study Drug Occurring in >10 % of Patients With Advanced Lung Cancer (N = 54)Tabled 1NSQ(n = 16)SQ-A(n = 15)SQ-B(n = 6)SCLC(n = 17)Total(N = 54)Any GradeGrade ≥3Any GradeGrade ≥3Any GradeGrade≥3Any GradeGrade ≥3Any GradeGrade ≥3Patients with ≥1 AE16 (100.0)11 (68.8)15 (100.0)13 (86.7)6 (100.0)2 (33.3)17 (100.0)13 (76.5)54 (100.0)39 (72.2)Anemia13 (81.3)2 (12.5)10 (66.7)2(13.3)5(83.3)1 (16.7)15(88.2)5(29.4)43(79.6)10 (18.5)Decreased WBC count11 (68.8)4 (25.0)13 (86.7)2(13.3)3(50.0)013(76.5)1(5.9)40(74.1)7(13.0)Decreased neutrophil count11 (68.8)6 (37.5)12 (80.0)11 (73.3)3(50.0)1 (16.7)13(76.5)8(47.1)39(72.2)26 (48.1)Decreased plateletcount7(43.8)2 (12.5)5(33.3)03(50.0)1 (16.7)8(47.1)4(23.5)23(42.6)7(13.0)Increased ALT7(43.8)1(6.3)4(26.7)2(13.3)2(33.3)07(41.2)020(37.0)3(5.6)Increased AST7(43.8)06(40.0)1(6.7)2(33.3)05(29.4)020(37.0)1(1.9)Asthenia8(50.0)1(6.3)7(46.7)02(33.3)02(11.8)019(35.2)1(1.9)Decreased appetite6(37.5)04(26.7)02(33.3)07(41.2)019(35.2)0Nausea3(18.8)06(40.0)02(33.3)07(41.2)1(5.9)18(33.3)1(1.9)Rash1(6.3)03(20.0)01(16.7)02(11.8)017(13.3)0Vomiting2(12.5)02(13.3)01(16.7)09(52.9)1(5.9)14(25.9)1(1.9)Thrombocytopenia3(18.8)03(20.0)1(6.7)007(41.2)5 (29.4)13(24.1)6(11.1)Alopecia1(6.3)07(46.7)0005(29.4)013(24.1)0Leukopenia2(12.5)000006(35.3)08(14.8)0Neutropenia3(18.8)1(6.3)00005(29.4)3 (17.6)8(14.8)4(7.4) Open table in a new tab Data presented as n (%). Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NSCLC, non-small cell lung cancer; NSQ, nonsquamous NSCLC; SCLC, small cell lung cancer; SQ-A, squamous NSCLC cohort A (tislelizumab + paclitaxel + cisplatin/ carboplatin); SQ-B, squamous NSCLC cohort B (tislelizumab + gemcitabine + cisplatin/ carboplatin); WBC, white blood cell. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese PatientsLung CancerVol. 147PreviewLung cancer is the leading cause of cancer-related death worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancers and is categorized into two histology types: nonsquamous (NSQ) and squamous (SQ) [2]. Small cell lung cancer (SCLC) is less prevalent than NSCLC and accounts for approximately 15–20% of all lung cancers [2,3]. Strategies for first-line treatment for advanced-stage lung cancer continue to evolve to address the high mortality rate. The FDA has approved combination therapy consisting of chemotherapy plus antibodies targeting either programmed cell death protein-1 (PD-1) or programmed death-ligand 1 (PD-L1) as first-line treatment for SQ NSCLC, NSQ NSCLC without EGFR or ALK mutations, as well as extensive-stage SCLC [4,5]. Full-Text PDF Open Access" @default.
• W3171690098 created "2021-06-22" @default.
• W3171690098 creator A5016412981 @default.
• W3171690098 creator A5020012075 @default.
• W3171690098 creator A5023874610 @default.
• W3171690098 creator A5024689200 @default.
• W3171690098 creator A5028631107 @default.
• W3171690098 creator A5036233749 @default.
• W3171690098 creator A5040296857 @default.
• W3171690098 creator A5049678335 @default.
• W3171690098 creator A5063835503 @default.
• W3171690098 creator A5073304157 @default.
• W3171690098 creator A5075486570 @default.
• W3171690098 creator A5075877965 @default.
• W3171690098 creator A5083283370 @default.
• W3171690098 creator A5091161457 @default.
• W3171690098 date "2021-08-01" @default.
• W3171690098 modified "2023-09-25" @default.
• W3171690098 title "Corrigendum to “A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients” [Lung Cancer 147 (2020) 259–268]" @default.
• W3171690098 doi "https://doi.org/10.1016/j.lungcan.2021.05.035" @default.
• W3171690098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34127281" @default.
• W3171690098 hasPublicationYear "2021" @default.
• W3171690098 type Work @default.
• W3171690098 sameAs 3171690098 @default.
• W3171690098 citedByCount "0" @default.
• W3171690098 crossrefType "journal-article" @default.
• W3171690098 hasAuthorship W3171690098A5016412981 @default.
• W3171690098 hasAuthorship W3171690098A5020012075 @default.
• W3171690098 hasAuthorship W3171690098A5023874610 @default.
• W3171690098 hasAuthorship W3171690098A5024689200 @default.
• W3171690098 hasAuthorship W3171690098A5028631107 @default.
• W3171690098 hasAuthorship W3171690098A5036233749 @default.
• W3171690098 hasAuthorship W3171690098A5040296857 @default.
• W3171690098 hasAuthorship W3171690098A5049678335 @default.
• W3171690098 hasAuthorship W3171690098A5063835503 @default.
• W3171690098 hasAuthorship W3171690098A5073304157 @default.
• W3171690098 hasAuthorship W3171690098A5075486570 @default.
• W3171690098 hasAuthorship W3171690098A5075877965 @default.
• W3171690098 hasAuthorship W3171690098A5083283370 @default.
• W3171690098 hasAuthorship W3171690098A5091161457 @default.
• W3171690098 hasBestOaLocation W31716900981 @default.
• W3171690098 hasConcept C120665830 @default.
• W3171690098 hasConcept C121332964 @default.
• W3171690098 hasConcept C126322002 @default.
• W3171690098 hasConcept C2776256026 @default.
• W3171690098 hasConcept C61511704 @default.
• W3171690098 hasConcept C71924100 @default.
• W3171690098 hasConcept C90924648 @default.
• W3171690098 hasConceptScore W3171690098C120665830 @default.
• W3171690098 hasConceptScore W3171690098C121332964 @default.
• W3171690098 hasConceptScore W3171690098C126322002 @default.
• W3171690098 hasConceptScore W3171690098C2776256026 @default.
• W3171690098 hasConceptScore W3171690098C61511704 @default.
• W3171690098 hasConceptScore W3171690098C71924100 @default.
• W3171690098 hasConceptScore W3171690098C90924648 @default.
• W3171690098 hasLocation W31716900981 @default.
• W3171690098 hasOpenAccess W3171690098 @default.
• W3171690098 hasPrimaryLocation W31716900981 @default.
• W3171690098 hasRelatedWork W1580426574 @default.
• W3171690098 hasRelatedWork W1970383787 @default.
• W3171690098 hasRelatedWork W2043123170 @default.
• W3171690098 hasRelatedWork W2089620537 @default.
• W3171690098 hasRelatedWork W2275480158 @default.
• W3171690098 hasRelatedWork W2371214482 @default.
• W3171690098 hasRelatedWork W2390152934 @default.
• W3171690098 hasRelatedWork W3095306390 @default.
• W3171690098 hasRelatedWork W4238089809 @default.
• W3171690098 hasRelatedWork W4241346791 @default.
• W3171690098 hasVolume "158" @default.
• W3171690098 isParatext "false" @default.
• W3171690098 isRetracted "false" @default.
• W3171690098 magId "3171690098" @default.
• W3171690098 workType "article" @default.